Healthcare / Medical Instruments & SuppliesLSE
$84.50
+1.00 (+1.20%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 16%
FCF escenarios
weak_data · normalized FCF $4.5M · quality 33.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
26/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$86M
P/E
N/A
•EV/EBITDA
595.9x
↑ROE
-12.0%
↓Gross Margin
51.7%
↑Debt/Equity
0.75
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-1.6%
FCF CAGR
—
FCF margin
-1.2%
FCF / Net income
0.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $191.7M · net income $-9.6M · FCF $-2.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $191.7M | $191.7M | $193.3M | $203.3M | $201.0M |
| Net Income | $-9.6M | $-9.6M | $-4.6M | $-997000.00 | $-6.3M |
| EBITDA | $14.5M | $14.5M | $17.5M | $17.3M | $8.3M |
| EPS | -0.09 | -0.09 | -0.05 | -0.01 | -0.07 |
| Gross Margin | 51.7% | 51.7% | 52.4% | 50.9% | 49.2% |
| Operating Margin | 3.0% | 3.0% | 3.1% | 1.4% | -0.6% |
| Net Margin | -5.0% | -5.0% | -2.4% | -0.5% | -3.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.75 | 0.75 | 0.67 | 0.60 | 0.65 |
| Current Ratio | 1.45 | 1.45 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-2.3M | $-2.3M | $4.5M | $6.9M | $502000.00 |
| Returns | |||||
| ROE | -12.0% | -12.0% | -5.0% | -1.0% | -5.9% |
| Valuation | |||||
| EV/EBITDA | 595.85 | 595.85 | 257.35 | 479.27 | 551.25 |
| P/B | 107.77 | 107.77 | 48.08 | 79.56 | 42.01 |
| Growth & Yield | |||||
| Revenue Growth | -0.9% | -0.9% | -4.9% | 1.2% | — |
| EPS Growth | -107.5% | -107.5% | -362.2% | 85.2% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+56.5%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.05 → -0.09
Residual
+56.5%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.